RxDoctor Payments Data

Stephen Matse, DO

Internal Medicine · Johnstown, PANPI 1427054642

Payments from drug & device makers

$8,316in general payments, 2019–2025

Across 611 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$991
  • AstraZeneca$756
  • Novo Nordisk$706
  • Lilly USA, LLC$626
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$420
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,310100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,316 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$43,826
Medicare patients
126
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$171,781
JardianceEmpagliflozin67$60,579
TrulicityDulaglutide36$46,739
XareltoRivaroxaban39$44,167
FarxigaDapagliflozin Propanediol27$31,439
OzempicSemaglutide12$21,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,389
TradjentaLinagliptin25$17,254
EntrestoSacubitril/Valsartan30$16,446
Breo ElliptaFluticasone/Vilanterol34$14,596
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$12,883
LinzessLinaclotide11$12,035
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$9,930
Atorvastatin Calcium590$8,855
Levothyroxine Sodium451$7,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$991$171,781195 claims
Boehringer IngelheimJardiance, Tradjenta$17$77,83392 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$295$47,86896 claims
Lilly USA, LLCTrulicity$626$46,73936 claims
Johnson & JohnsonXarelto$170$44,16739 claims
AstraZenecaFarxiga$756$31,43927 claims
Novo NordiskOzempic$706$21,01112 claims
NovartisEntresto$180$16,44630 claims
AbbVieLinzess, Synthroid$1,820$14,47972 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →